August 8 2024

Bavarian Nordic Receives $1.568 Billion from US for Smallpox Vaccine Production

August 8, 2024

Bavarian Nordic AS, a Danish biotechnology company, has announced a new order worth $1.568 billion from the US government for additional production of its smallpox vaccine, IMVANEX.

The contract also includes $17 million for additional services between 2025 and 2027, such as vaccine storage.

The US Department of Health and Human Services (HHS) facilitated the agreement between Bavarian Nordic and Grand River Aseptic Manufacturing, Inc., a Michigan-based company that will manufacture and supply the vaccine.

The contract will aid in replenishing the bulk vaccine inventory needed for producing and supplying freeze-dried vaccines in the future.

IMVANEX is a live, attenuated vaccine approved for preventing smallpox and monkeypox in adults by the US Food and Drug Administration (FDA).

Bavarian Nordic's CEO, Paul Chaplin, stated, "This order is a significant milestone in our ongoing partnership with the US government to ensure the availability of critical vaccines for public health preparedness."